Physician profile
Taylor Caitlin Johnson
NPI 1285157461
$3,656.21
in general payments reported to CMS, 2019-2025
26 companies · $319 in 2025
The $319 reported for 2025 was more than what 76% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,032 · 2022: $696 · 2023: $841 · 2024: $769 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888 · Education: $40.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.07 |
| Education | $40.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.56 | 2021-2025 | |
| Astellas Pharma US INC | $409.42 | 2023-2025 | Veozah |
| Novo Nordisk INC | $295.33 | 2021-2025 | Wegovy, Saxenda |
| Pfizer INC. | $278.69 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $265.64 | 2021 | |
| Exeltis, USA INC. | $262.79 | 2021-2024 | Slynd |
| Biohaven Pharmaceutical Holding Company LTD. | $190.56 | 2022 | |
| Therapeuticsmd, INC. | $189.78 | 2021-2022 | |
| Antares Pharma, INC. | $133.27 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Lilly USA, LLC | $117.69 | 2021-2025 | Zepbound, Jardiance |
| Millicent US INC | $95.59 | 2024-2025 | Intrarosa |
| Hologic Sales and Service, LLC | $73.70 | 2021-2024 | Myosure Tissue Removal Device |
| Halozyme INC | $68.85 | 2023 | |
| Sun Pharmaceutical Industries INC. | $68.03 | 2024 | |
| Scynexis, INC. | $59.72 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $48.48 | 2022 | |
| Acerus Pharmaceuticals Corporation | $26.31 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $24.93 | 2025 | Myfembree |
| Azurity Pharmaceuticals, INC. | $24.89 | 2025 | Azmiro |
| Mayne Pharma Commercial LLC | $22.49 | 2023 | |
| Ironshore Pharmaceuticals INC. | $17.27 | 2024 | |
| Axonics, INC. | $15.53 | 2024 | Axonics, Bulkamid |
| Shield Therapeutics INC | $14.35 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.25 | 2023 | Trintellix |
| Actelion Pharmaceuticals US, INC. | $13.66 | 2022 | |
| Collegium Pharmaceutical, INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.